Optimal use and interpretation of the aldosterone renin ratio to detect aldosterone excess in hypertension

Journal of Human Hypertension

Volumn 20, Issue 7, 2006, Pages 482-489

  Doi, S A R ^a   Abalkhail, S ^a   Al Qudhaiby, M M ^a   Al Humood, K ^a   Hafez, M F ^a   Al Shoumer, K A S ^a  

^a MUBARAK AL KABEER HOSPITAL   (Kuwait)

Author keywords

Aldosterone renin ratio; Hypertension; Primary hyperaldosteronism

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FLUDROCORTISONE ACETATE; FOSINOPRIL; FUROSEMIDE; HYDRALAZINE; IRBESARTAN; MINOXIDIL; NIFEDIPINE; RENIN; SODIUM CHLORIDE; SPIRONOLACTONE; VERAPAMIL;

ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE SEVERITY; ESSENTIAL HYPERTENSION; HORMONE SYNTHESIS; HUMAN; PLASMA RENIN ACTIVITY; PREDICTION; PRIMARY HYPERALDOSTERONISM; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SAFETY; SALT LOADING; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; CAPTOPRIL; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; RENIN; SENSITIVITY AND SPECIFICITY;

EID: 33745278019     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002024     Document Type: Review

References (64)

1. Hemmelgarn BR, McAllister FA, Myers MG, McKay DW, Bolli P, Abbott C et al. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2005; 21: 645-656.
2. Mulatero P, Dluhy RG, Giacchetti G, Boscaro M, Veglio F, Stewart PM. Diagnosis of primary aldosteronism: From screening to subtype differentiation. Trends Endocrinol Metab 2005; 16: 114-119.
3. Ganguly A. Primary aldosteronism. N Engl J Med 1998; 339: 1828-1834.
4. Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, Klemm SA. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993; 20: 296-298.
5. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315-318.
6. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young Jr WF. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85: 2854-2859.
7. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L et al. Primary hyperaldosteronism in essential hypertensives: Prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-1867.
8. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40: 897-902.
9. Kaplan NM. Cautions over the current epidemic of primary aldosteronism. Lancet 2001; 357: 953-954.
10. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89: 1045-1050.
11. Stowasser M, Gordon RD. Primary aldosteronism - careful investigation is essential and rewarding. Mol Cell Endocrinol 2004; 217: 33-39.
12. Blumenfeld JD, Laragh JH. Renin system analysis: A rational method for the diagnosis and treatment of the individual patient with hypertension. Am J Hypertens 1998; 11: 894-896.
13. McKenna TJ, Sequeira SJ, Heffernan A, Chambers J, Cunningham S. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab 1991; 73: 952-957.
14. Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 1981; 141: 1589-1593.
15. Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med 1993; 153: 2125-2129.
16. Young Jr WF. Minireview: Primary aldosteronism - changing concepts in diagnosis and treatment. Endocrinology 2003; 144: 2208-2213.
17. Tiu SC, Choi CH, Shek CC, Ng YW, Chan FK, Ng CM et al. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab 2005; 90: 72-78.
18. Montori VM, Young Jr WF. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am 2002; 31: 619-632, xi.
19. Lim PO, MacDonald TM. Primary aldosteronism, diagnosed by the aldosterone to renin ratio, is a common cause of hypertension. Clin Endocrinol (Oxford) 2003; 59: 427-430.
20. Baas SJ, Endert E, Fliers E, Prummel MF, Wiersinga WM. Establishment of reference values for endocrine tests. III: Primary aldosteronism. Neth J Med 2003; 61: 37-43.
21. Hamlet SM, Tunny TJ, Woodland E, Gordon RD. Is aldosterone/renin ratio useful to screen a hypertensive population for primary aldosteronism? Clin Exp Pharmacol Physiol 1985; 12: 249-252.
22. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: Diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 2005; 51: 386-394.
23. Nishizaka MK, Pratt-Ubunama M, Zaman MA, Cofield S, Calhoun DA. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 2005; 18: 805-812.
24. Gordon RD. Mineralocorticoid hypertension. Lancet 1994; 344: 240-243.
25. Kater CE, Biglieri EG. The syndromes of low-renin hypertension: 'separating the wheat from the chaff'. Arq Bras Endocrinol Metabol 2004; 48: 674-681.
26. Sealey JE, Gordon RD, Mantero F. Plasma renin and aldosterone measurements in low renin hypertensive states. Trends Endocrinol Metab 2005; 16: 86-91.
27. Young Jr WF. Primary aldosteronism: A common and curable form of hypertension. Cardiol Rev 1999; 7: 207-214.
28. Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002; 15: 896-902.
29. Hambling C, Jung RT, Gunn A, Browning MC, Bartlett WA. Re-evaluation of the captopril test for the diagnosis of primary hyperaldosteronism. Clin Endocrinol (Oxford) 1992; 36: 499-503.
30. Lyons DF, Kem DC, Brown RD, Hanson CS, Carollo ML. Single dose captopril as a diagnostic test for primary aldosteronism. J Clin Endocrinol Metab 1983; 57: 892-896.
31. Agharazii M, Douville P, Grose JH, Lebel M. Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension 2001; 37: 1440-1443.
32. Castro OL, Yu X, Kem DC. Diagnostic value of the post-captopril test in primary aldosteronism. Hypertension 2002; 39: 935-938.
33. Trenkel S, Seifarth C, Schobel H, Hahn EG, Hensen J. Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism. Exp Clin Endocrinol Diabetes 2002; 110: 80-85.
34. Perschel FH, Schemer R, Seiler L, Reincke M, Deinum J, Maser-Gluth C et al. Rapid screening test for primary hyperaldosteronism: Ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clin Chem 2004; 50: 1650-1655.
35. Ferrari P, Shaw SG, Nicod J, Saner E, Nussberger J. Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertens 2004; 22: 377-381.
36. Racine MC, Douville P, Lebel M. Functional tests for primary aldosteronism: Value of captopril suppression. Curr Hypertens Rep 2002; 4: 245-249.
37. Gordon RD. Primary aldosteronism. J Endocrinol Invest 1995; 18: 495-511.
38. Vallotton MB, Rossier MF, Capponi AM. Potassium-angiotensin interplay in the regulation of aldosterone biosynthesis. Clin Endocrinol (Oxford) 1995; 42: 111-119.
39. Nomura K, Toraya S, Horiba N, Ujihara M, Aiba M, Demura H. Plasma aldosterone response to upright posture and angiotensin II infusion in aldosterone producing adenoma. J Clin Endocrinol Metab 1992; 75: 323-327.
40. Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol (Oxford) 2002; 57: 457-465.
41. Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaki T, Takano K. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab 2003; 88: 2489-2494.
42. Bravo EL. Primary aldosteronism. Issues in diagnosis and management. Endocrinol Metab Clin North Am 1994; 23: 271-283.
43. Nishizaka MK, Calhoun DA. Primary aldosteronism: Diagnostic and therapeutic considerations. Curr Cardiol Rep 2005; 7: 412-417.
44. Hirohara D, Nomura K, Okamoto T, Ujihara M, Takano K. Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives. J Clin Endocrinol Metab 2001; 86: 4292-4298.
45. Ogawa K, Matsunaga M, Pak CH, Hara A, Kawai C. Synchronous changes in active and inactive renin secretion after furosemide in patients with primary aldosteronism. Clin Exp Hypertens A 1984; 6: 1459-1467.
46. Honda M, Izumi Y, Tsuchiya M, Ueda Y, Watanabe H, Inoue T et al. A simplified screening test for differentiating primary aldosteronism from essential hypertension with low plasma renin activity. Jpn Circ J 1980; 44: 719-725.
47. Vallotton MB. Primary aldosteronism. Part I. Diagnosis of primary hyperaldosteronism. Clin Endocrinol (Oxford) 1996; 45: 47-52.
48. Weinberger MH, Grim CE, Hollifield JW, Kem DC, Ganguly A, Kramer NJ et al. Primary aldosteronism: Diagnosis, localization, and treatment. Ann Intern Med 1979; 90: 386-395.
49. Gosse P, Guiheneuf-Tobie C, Lasserre R, Minifie C, Lemetayer P, Clementy J. Biochemical detection of Conn's adenoma: Definition of criteria and reference values. Arch Mal Coeur Vaiss 2005; 98: 181-185.
50. Prejbisz A, Postula M, Cybulska I, Dobrucki T, Kabat M, Peczkowska M et al. The role of biochemical tests and clinical symptoms in differential diagnosis of primary aldosteronism. Kardiol Pol 2003; 58: 17-26.
51. Unger N, Lopez Schmidt I, Pitt C, Walz MK, Philipp T, Mann K et al. Comparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass. Eur J Endocrinol 2004; 150: 517-523.
52. Seiler L, Rump LC, Schulte-Monting J, Slawik M, Borm K, Pavenstadt H et al. Diagnosis of primary aldosteronism: Value of different screening parameters and influence of antihypertensive medication. Eur J Endocrinol 2004; 150: 329-337.
53. Rayner BL. Screening and diagnosis of primary aldosteronism. Cardiovasc J S Afr 2002; 13: 166-170.
54. Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N, Slater GJ. Diagnosis and management of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2001; 2: 156-169.
55. Kem DC, Mayes D, Weinberger M, Nugent CA. Saline suppression of plasma aldosterone and plasma renin activity in hypertension. Ariz Med 1971; 28: 264-266.
56. Streeten DH, Tomycz N, Anderson CH. Reliability of screening methods for the diagnosis of primary aldosteronism. Am J Med 1979; 67: 403-413.
57. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: Plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37: 699-705.
58. Carpene G, Rocco S, Opocher G, Mantero F. Acute and chronic effect of nifedipine in primary aldosteronism. Clin Exp Hypertens A 1989; 11: 1263-1272.
59. Brown MJ, Hopper RV. Calcium-channel blockade can mask the diagnosis of Conn's syndrome. Postgrad Med J 1999; 75: 235-236.
60. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000; 14: 311-315.
61. Hood S, Cannon J, Foo R, Brown M. Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing. Clin Med 2005; 5: 55-60.
62. Griffing GT, Melby JC. The therapeutic effect of a new angiotensin-converting enzyme inhibitor, enalapril maleate, in idiopathic hyperaldosteronism. J Clin Hypertens 1985; 1: 265-276.
63. Lamarre-Cliche M, de Champlain J, Lacourciere Y, Poirier L, Karas M, Larochelle P. Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives. Am J Hypertens 2005; 18: 56-64.
64. Gordon MS, Williams GH, Hollenberg NK. Renal and adrenal responsiveness to angiotensin II: Influence of beta adrenergic blockade. Endocr Res 1992; 18: 115-131.